Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas

Tina A. Ayeni, Jamie N. Bakkum-Gamez, Andrea Mariani, Michaela E. McGree, Amy L. Weaver, Michael G. Haddock, Gary L. Keeney, Harry J. Long, Sean C. Dowdy, Karl C. Podratz

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Objective The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes. Methods Patient-, disease-, and treatment-specific variables were annotated. Survival was estimated via the Kaplan-Meier method. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios. Results From 1999 through 2008, therapy with curative intent was initiated for 119 grade 3 endometrioid (G3EC), 211 serous (USC), and 40 clear cell (CCC) carcinomas. Although clinicopathologic risk factors varied among the histologic subtypes, overall survival (OS) did not differ statistically between subtypes (P =.10) or in stage-for-stage comparative analyses (stage I/II, P =.45; stage III, P =.46; stage IV, P =.65). The 5-year cause-specific survival in stage I/II was 84.8%, 89.8%, and 83.9% for G3EC, USC, and CCC, respectively; multivariable modeling identified lymphovascular space involvement (LVSI) as the only independent prognostic factor (P =.02). For stage III, 5-year OS was 49.2% and 40.0% for G3EC and USC, respectively; multivariable modeling identified age (P <.001), LVSI (P <.001), unresectable nodal disease (P =.03), and regional radiotherapy (P =.01) as independent prognostic factors. For stage IV, 5-year OS was 8.7% and 12.1% for G3EC and USC, respectively; multivariable modeling identified LVSI (P =.002), cervical stromal invasion (P =.02), and adjuvant chemotherapy (P =.02) but not residual disease as independent prognostic factors. Conclusions When controlled for disease stage, outcomes did not differ among high-risk histologic subtypes. LVSI was a significant adverse prognostic factor within all stages. The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority.

Original languageEnglish (US)
Pages (from-to)478-485
Number of pages8
JournalGynecologic oncology
Issue number3
StatePublished - Jun 2013


  • Clinicopathologic prognostic factors
  • High-risk uterine carcinomas
  • Outcomes assessment

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas'. Together they form a unique fingerprint.

Cite this